Predicting contralateral extraprostatic extension in unilateral high-risk prostate cancer: a multicentric external validation study

被引:0
|
作者
Diamand, Romain [1 ]
Roche, Jean-Baptiste [2 ]
Lacetera, Vito [3 ]
Simone, Giuseppe [4 ]
Windisch, Olivier [5 ]
Benamran, Daniel [5 ]
Fourcade, Alexandre [6 ]
Fournier, Georges [6 ]
Fiard, Gaelle [7 ]
Ploussard, Guillaume [8 ]
Roumeguere, Thierry [1 ]
Peltier, Alexandre [1 ]
Albisinni, Simone [1 ,9 ]
机构
[1] Univ Libre Bruxelles, Erasme Hosp, Hop Univ Bruxelles, Jules Bordet Inst,Dept Urol, Rue Meylemeersch 90, B-1070 Brussels, Belgium
[2] Clin St Augustin, Dept Urol, Bordeaux, France
[3] Azienda Osped Ospedali Riuniti Marche Nord, Dept Urol, Pesaro, Italy
[4] IRCCS Regina Elena Natl Canc Inst, Dept Urol, Rome, Italy
[5] Hop Univ Geneve, Dept Urol, Geneva, Switzerland
[6] CHRU Brest, Hop Cavale Blanche, Dept Urol, Brest, France
[7] Univ Grenoble Alpes, Grenoble Alpes Univ Hosp, Dept Urol, CNRS,Grenoble INP,TIMC, Grenoble, France
[8] La Croix Du Sud Hosp, Dept Urol, Quint Fonsegrives, France
[9] Tor Vergata Univ, Dept Surg Sci, Urol Unit, Rome, Italy
关键词
Radical prostatectomy; High-risk; Prostate cancer; Nerve sparing; Extraprostatic extension;
D O I
10.1007/s00345-024-04966-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
PurposeAccurate prediction of extraprostatic extension (EPE) is crucial for decision-making in radical prostatectomy (RP), especially in nerve-sparing strategies. Martini et al. introduced a three-tier algorithm for predicting contralateral EPE in unilateral high-risk prostate cancer (PCa). The aim of the study is to externally validate this model in a multicentric European cohort of patients.MethodsThe data from 208 unilateral high-risk PCa patients diagnosed through magnetic resonance imaging (MRI)-targeted and systematic biopsies, treated with RP between January 2016 and November 2021 at eight referral centers were collected. The evaluation of model performance involved measures such as discrimination (AUC), calibration, and decision-curve analysis (DCA) following TRIPOD guidelines. In addition, a comparison was made with two established multivariable logistic regression models predicting the risk of side specific EPE for assessment purposes.ResultsOverall, 38%, 48%, and 14% of patients were categorized as low, intermediate, and high-risk groups according to Martini et al.'s model, respectively. At final pathology, EPE on the contralateral prostatic lobe occurred in 6.3%, 12%, and 34% of patients in the respective risk groups. The algorithm demonstrated acceptable discrimination (AUC 0.68), comparable to other multivariable logistic regression models (p = 0.3), adequate calibration and the highest net benefit in DCA. The limitations include the modest sample size, retrospective design, and lack of central revision.ConclusionOur findings endorse the algorithm's commendable performance, supporting its utility in guiding treatment decisions for unilateral high-risk PCa patients.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Recent advances in high-risk prostate cancer surgery
    Ploussard, G.
    Sargos, P.
    Beauval, J-B
    Roupret, M.
    Latorzeff, I
    CANCER RADIOTHERAPIE, 2021, 25 (6-7): : 655 - 659
  • [22] High-risk localized prostate cancer: Integrating chemotherapy
    Oh, WK
    ONCOLOGIST, 2005, 10 : 18 - 22
  • [23] High-risk prostate cancer: the role of surgical management
    Morlacco, Alessandro
    Karnes, R. Jeffrey
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 102 : 135 - 143
  • [24] External Validation of a Prediction Model for Side-specific Extraprostatic Extension of Prostate Cancer at Robot-assisted Radical Prostatectomy
    Veerman, Hans
    Heymans, Martijn W.
    van der Poel, Henk G.
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 37 : 50 - 52
  • [25] Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease
    Tolonen, Teemu T.
    Riikonen, Jarno
    Tammela, Teuvo L. J.
    Koivusalo, Laura
    Haapasalo, Hannu
    Kujala, Paula
    Kaipia, Antti
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2018, 35 : 80 - 84
  • [26] Neoadjuvant and adjuvant treatment in high-risk prostate cancer
    Bandini, Marco
    Fossati, Nicola
    Gandaglia, Giorgio
    Preisser, Felix
    Dell'Oglio, Paolo
    Zaffuto, Emanuele
    Stabile, Armando
    Gallina, Andrea
    Suardi, Nazareno
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    Briganti, Alberto
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 425 - 438
  • [27] Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension
    Sayyid, Rashid
    Perlis, Nathan
    Ahmad, Ardalanejaz
    Evans, Andrew
    Toi, Ants
    Horrigan, Michael
    Finelli, Antonio
    Zlotta, Alexandre
    Kulkarni, Girish
    Hamilton, Robert
    Morash, Christopher
    Fleshner, Neil
    BJU INTERNATIONAL, 2017, 120 (01) : 76 - 82
  • [28] External Tertiary-Care-Hospital Validation of the Epidemiological SEER-Based Nomogram Predicting Downgrading in High-Risk Prostate Cancer Patients Treated with Radical Prostatectomy
    Garcia, Cristina Cano
    Wenzel, Mike
    Piccinelli, Mattia Luca
    Hoeh, Benedikt
    Landmann, Lea
    Tian, Zhe
    Humke, Clara
    Incesu, Reha-Baris
    Koellermann, Jens
    Wild, Peter J.
    Wurnschimmel, Christoph
    Graefen, Markus
    Tilki, Derya
    Karakiewicz, Pierre I.
    Kluth, Luis A.
    Chun, Felix K. H.
    Mandel, Philipp
    DIAGNOSTICS, 2023, 13 (09)
  • [29] External validation of a nomogram for unilateral pelvic lymph node dissection in prostate cancer
    Ortner, Gernot
    Falkenbach, Fabian
    Kachanov, Mykyta
    Inderhees, Tim
    Maurer, Tobias
    Knipper, Sophie
    Graefen, Markus
    Budaeus, Lars
    BJU INTERNATIONAL, 2025,
  • [30] Assessment of Diagnostic Performance of Risk Factors Affecting Extraprostatic Extension: Role of Zonal Level of Prostate Cancer
    Park, Seo Young
    Jeon, Ga young
    CURRENT MEDICAL IMAGING, 2024, 20